The global cluster headache market is anticipated to grow at a significant CAGR during the forecast period. Cluster headache can be defined as the high-intensity pain observed by the patient on either side of the brain. During a cluster cycle, brief and excruciatingly severe headache attacks recur around 1 to 8 times during the course of a day. Factor such as a major change in the lifestyle of people that includes excessive screen time, alcohol usage, and smoking is driving the market of cluster headache across the globe. Further, the increasing R&D activities by the market players are expected to provide growth opportunities to the market in the near future. For instance, in October 2019, Zosano Pharma Corp. announced that the company has begun enrolling cluster headache patients in the ATAC clinical trial. This Phase 2/3 study will evaluate the efficacy of C213 for the acute treatment of cluster headache.

However, the limited availability of drugs for the treatment of cluster headache is one of the major factors that is anticipated to slow the growth of the global cluster headache market. For instance, till now there are only three companies in total that include Teva Pharmaceutical Industries Ltd., Eli Lilly and Co., and Novartis AG to have the FDA approval for drug manufacturing for cluster headache across the globe. Additionally, a lack of awareness amongst people coupled with the difficulty in diagnosis will also impact the market growth of the global cluster headache market. The pain observed in the cluster headache doesn’t have any specific pattern and most of the time patient as well as a physician gets confused and considers it migraine since there is no specific test for the diagnosis.

Segmental Outlook 

The global cluster headache market is segmented on the basis of type and drug type. On the basis of type, the market is bifurcated into episodic cluster headache and chronic cluster headache. Episodic cluster headache is more common than chronic cluster headache and hence contributes a significant share to the market. Based on drug type, the market is sub-segmented into fast-acting drugs, long-term drugs, and short-term drugs. 

Global Cluster Headache Market Share by Drug Type, 2018 (%)

Fast-acting drugs will be the largest segment by drug type

Based on the drug type, the market is segmented into fast-acting drugs, long-term drugs, and short-term drugs. Among these, the fast-acting drugs is anticipated to hold the largest market share owing to increasing cases of cluster headache across the globe. Hence, with the increasing patient population of cluster headache, the focus is majorly on providing patients with the instant and fast relief from the pain. A number of pharma companies are also focusing more on producing fast relief drugs for the pain management of cluster headache hence driving the global cluster headache market growth. Along with the fast relief drug segment, the long-term drug segment is anticipated to grow considerably during the forecast period. 

Regional Outlooks

The global cluster headache market is geographically segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America along with Europe is expected to contribute a significant market share during the forecast period.  According to the European Headache Alliance (EHA), more than 600,000 people in Europe live with cluster headache, and out of which only less than 50% of them consult any specialist. In addition, of all the people suffering from cluster headache in Europe, more than one-third of them have to miss work due to the condition, at a cost of $7 billion per year.

Global cluster headache Market Growth by Region, 2019-2025

Asia-Pacific to Augment with the Fastest Growth Rate in the Global Cluster Headache Market 

Asia-Pacific is anticipated to grow at the fastest growth rate in the global cluster headache market due to the increasing trend towards the preventive treatment and growing pharmaceutical industry in emerging economies such as India, China, and others. The inclination of the major pharmaceutical companies towards the emerging market of Asia-Pacific is further estimated to propel the market growth during the forecast period. In addition, various research institutes and investments made by the government and non-government organizations for the treatment and development of drugs would boost the cluster headache market considerably in the Asia Pacific.

Market Players Outlook

Some of the key players operating in the global cluster headache market include Eli Lilly and Co., Novartis International AG, AstraZeneca PLC, Pfizer Inc., GlaxoSmithKline PLC, and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, mergers, and acquisition, collaborations with the government, to stay competitive in the market. For instance, in June 2019, Eli Lilly and Co. received the US Food and Drug Administration (FDA) clearance for the Emgality (galcanezumab-gnlm) injection (300 mg) that can be used for the treatment of episodic cluster headache in adults.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global cluster headache market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.